Home › NDC Lookup › Ingredients › Human Rho(D) Immune Globulin › 44206-0300-01
🧴image loading
(from DailyMed)

Rhophylac HUMAN RHO(D) IMMUNE GLOBULIN 1500 [iU]/2mL Solution — NDC 44206-300-01 (Billing 44206-0300-01)

by CSL Behring AG · 1 SYRINGE, GLASS in 1 CARTON / 2 mL in 1 SYRINGE, GLASS

This is a package of Rhophylac HUMAN RHO(D) IMMUNE GLOBULIN 1500 [iU]/2mL Solution from CSL Behring AG, marketed since Jan 2009 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.

NDC 44206-0300-01
🏷️ FDA NDC (as labeled) 44206-300-01 billing pads the product segment with a zero
This package
Contains2 mL in 1 syringe, glass Medicaid pays$108.13 / unit · 12 mo Per package$216.26 / 2 ml · Medicaid Pack sizes2 compare ↓
Main listing for product 44206-300 · Also comes in: 10 syringes 44206-300-10
Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 44206-300-01 alone.

Record
FDA NDC Directory package listing · Plasma derivative
Code segments
44206 labeler · 300 product · 01 package
Package marketed since
Jan 6, 2009
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 4420630001 5
Medicaid fills, this package
12,972 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 44206-300-01
Product NDC 44206-300
11-digit billing NDC 44206030001
NCPDP billing unit ML — per mL (volume)
Application # BLA125070
SPL Set ID 32c1f783-bd20-45bc-98d8-cdd5efa9f0d6
Established class (EPC) Human Immunoglobulin G
Mechanism of action Endogenous Antigen Neutralization
Physiologic effect Passively Acquired Immunity
Chemical class Immunoglobulins
DEA schedule Non-controlled
Marketing category BLA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2009-01-06
Route INTRAMUSCULAR, INTRAVENOUS
Dosage form SOLUTION
Substance HUMAN RHO(D) IMMUNE GLOBULIN
Biologic (Purple Book) 351(a)

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 1910005000E550
GPI class Rhophylac
GCN Seq No 053742
GCN 21467
HICL code 004209
Ingredient (HICL) Rho(D) Immune Globulin
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W7
Therapeutic class — intermediate (HIC2) Biologicals
HIC3 code W7K
Therapeutic class — specific (HIC3) Antisera
AHFS code 80:04.00.00
AHFS class Antitoxins And Immune Globulins
FDB label name RHOPHYLAC 300 MCG/2 ML SYRINGE
FDB brand name Rhophylac
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 053742
  • GCN: 21467
  • GPI-14 (Medi-Span): 1910005000E550
  • HICL (First Databank): 004209
  • AHFS class code: 80:04.00.00
Why two NDCs? The FDA registers this code as 44206-300-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 44206-0300-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name RHOPHYLAC 300 MCG/2 ML SYRINGE Ingredient Rho(D) Immune Globulin

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $108.13 $216.26 / 2 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J2791 $4.878 / J2791 unit —
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)44206-300-01
11-digit billing NDC44206-0300-01
Format5-3-2 as registered → padded to 5-4-2 for billing (zero added to the product segment)
HCPCS J-codeJ2791
DescriptorINJECTION, RHO(D) IMMUNE GLOBULIN (HUMAN), (RHOPHYLAC), INTRAMUSCULAR OR INTRAVENOUS, 100 IU
Billing units / pkg7.5 units
How the units are derivedThis package is 2 ML; the HCPCS unit is 100 IU, so one package = 7.5 billing units.
Medicare Part B spend (2025 (Q1-Q4))$2,419 · 38 claims · $63.66 per claim (all NDCs under J2791)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
44206-0300-01 You're viewing this Main listing 1 SYRINGE, GLASS in 1 CARTON / 2 mL in 1 SYRINGE, GLASS 2009-01-06 — Active
44206-0300-10 44206-300-10 10 SYRINGE, GLASS in 1 CARTON / 2 mL in 1 SYRINGE, GLASS 2009-01-06 — Active

In Medicaid, this is the most-dispensed pack of this product — about 89% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 syringe, glass in 1 carton / 2 ml in 1 syringe, glass.
What NDC number is used to bill for this package of Rhophylac HUMAN RHO(D) IMMUNE GLOBULIN 1500 [iU]/2mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Rhophylac 1500 [iU]/2mLthis 44206-0300-01 CSL 1 syringe — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
2004
First FDA approval
Feb 2004
📍
2026
Currently FDA-listed
22 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCSL Behring AG
FDA applicationBLA125070 (BLA)
Labeler code44206
First marketedJan 2009
Product typePlasma Derivative
Portfolio14 products on file

More NDCs from CSL Behring AG labeler code 44206

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
13K
Units reimbursed last 4 qtrs
12.6K
Gross reimbursed last 4 qtrs
$1.36M
Avg / prescription
$104.73
Avg / unit
$108.12
Latest quarter Q1 2026
2.5KRx
Fee-for-service vs managed care ⓘ
25% FFS 75% MCO
Fee-for-service · 3,301 Rx Managed care · 9,671 Rx
State Medicaid map
Alaska: no data reported AK Maine: 56 units · 4.0 per 100k residents ME Washington: no data reported WA Idaho: 196 units · 10.0 per 100k residents ID Montana: 105 units · 9.3 per 100k residents MT North Dakota: 72 units · 9.2 per 100k residents ND Minnesota: 241 units · 4.2 per 100k residents MN Wisconsin: 540 units · 9.1 per 100k residents WI Michigan: 95 units · 0.9 per 100k residents MI New York: 241 units · 1.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 213 units · 5.0 per 100k residents OR Nevada: 257 units · 8.0 per 100k residents NV Wyoming: no data reported WY South Dakota: 107 units · 11.6 per 100k residents SD Iowa: 219 units · 6.8 per 100k residents IA Illinois: 432 units · 3.4 per 100k residents IL Indiana: 943 units · 13.7 per 100k residents IN Ohio: 451 units · 3.8 per 100k residents OH Pennsylvania: 301 units · 2.3 per 100k residents PA New Jersey: 144 units · 1.6 per 100k residents NJ Massachusetts: 266 units · 3.8 per 100k residents MA California: 392 units · 1.0 per 100k residents CA Utah: 8 units · 0.2 per 100k residents UT Colorado: 228 units · 3.9 per 100k residents CO Nebraska: 239 units · 12.1 per 100k residents NE Missouri: 405 units · 6.5 per 100k residents MO Kentucky: 186 units · 4.1 per 100k residents KY West Virginia: 61 units · 3.4 per 100k residents WV Virginia: 358 units · 4.1 per 100k residents VA Maryland: 98 units · 1.6 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 34 units · 0.5 per 100k residents AZ New Mexico: 69 units · 3.3 per 100k residents NM Kansas: 164 units · 5.6 per 100k residents KS Arkansas: 244 units · 8.0 per 100k residents AR Tennessee: 590 units · 8.3 per 100k residents TN North Carolina: 870 units · 8.0 per 100k residents NC South Carolina: 315 units · 5.9 per 100k residents SC Delaware: 133 units · 12.9 per 100k residents DE Oklahoma: 287 units · 7.1 per 100k residents OK Louisiana: 236 units · 5.2 per 100k residents LA Mississippi: 188 units · 6.4 per 100k residents MS Alabama: 184 units · 3.6 per 100k residents AL Georgia: 90 units · 0.8 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 1,250 units · 4.1 per 100k residents TX Florida: 1,057 units · 4.7 per 100k residents FL
Units reimbursed · per 100k residents
0.213.7
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Indiana 13.7 /100k
2 Delaware 12.9 /100k
3 Nebraska 12.1 /100k
4 South Dakota 11.6 /100k
5 Idaho 10.0 /100k
6 Montana 9.3 /100k
7 North Dakota 9.2 /100k
8 Wisconsin 9.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 syringe this page44206-0300-01 12,972 Rx · $1,358,622
10 syringes44206-0300-10 1,592 Rx · $163,752
Drug total (last 4 qtrs): 14,564 Rx · 14,103 units · $1,522,373 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

About this NDC listing & data coverage

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by CSL Behring AG. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 10 syringes (44206-0300-10). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
CSL Behring AG is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J2791 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 44206-0251-05 · CSL 44206-0310-25 · CSL →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.